Final Report
This final progress report describes the development of the CANDO Software package at ThirdLaw Technologies LLC (TLT) towards a software platform that will be used by its subsidiary company ThirdLaw Molecular LLC (TLM) for the development of therapeutic Spiroligomer™ molecules. ThirdLaw Molecular LLC is 95% owned by ThirdLaw Technologies LLC. TLM is developing a new therapeutics platform based on Spiroligomer™ molecules and is currently funded by the Department of Defense, Defense Threat Reduction Agency (DOD/DTRA W15QKN209C004). Spiroligomer™ molecules are complex, highly-preorganized macromolecules with programmable three-dimensional shapes. Spiroligomer™ molecules are currently synthesized by TLM in the form of large (>880,000 member) DNA-encoded libraries and screened against dangerous bacteria and viruses as part of the DOD/DTRA project. The CANDO software package is being developed to enable the computational design of Spiroligomer™ molecules for the development of therapeutic and diagnostic molecules. Towards this end, over the period of the grant we implemented software algorithms and a user interface within CANDO to enable the computational design of Spiroligomer™ molecules.